Shen, Bo MD, FACG1; Fleshner, Philip MD, FACS, FASCRS2,3; Shah, Samir A. MD, FACG4
doi : 10.14309/ajg.0000000000001084
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 621-624
Forde, Justin MD1; Carrion, Andres F. MD1; Pearlman, Michelle MD1
doi : 10.14309/ajg.0000000000001086
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 625-627
Long, Yi MM1; Lv, Xiuhe MD1; Tang, Li NP1; Yang, Jinlin MD1
doi : 10.14309/ajg.0000000000000736
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 628
Chen, Kan MD1; Liu, Feng MD1
doi : 10.14309/ajg.0000000000000695
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 629
Syed, Taseen MBBS, MD1,2; Siddiqui, Bilal MD1,2; Zot, Patricija MD3; Vachhani, Ravi MD1
doi : 10.14309/ajg.0000000000000746
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 630
Kotani, Kohei MD, PhD1; Uchida-Kobayashi, Sawako MD, PhD1; Yoshida, Kanako MD, PhD1; Kawamura, Etsushi MD, PhD1; Fujii, Hideki MD, PhD1; Hagihara, Atsushi MD, PhD1; Enomoto, Masaru MD, PhD1; Tamori, Akihiro MD, PhD1; Kawada, Norifumi MD, PhD1
doi : 10.14309/ajg.0000000000000747
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 631
Zhang, Xiangyu MS1,†; Mi, Jinye MS1,2,†; Song, Lianxi MS1,2,†; Lizaso, Analyn MD3; Yang, Nong MD1; Zhang, Yongchang MD1
doi : 10.14309/ajg.0000000000000755
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 632
Lew, Daniel MD1; Jamil, Laith MD2; Lo, Simon K. MD1; Rezaie, Ali MD1
doi : 10.14309/ajg.0000000000000941
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 633
doi : 10.14309/ajg.0000000000001123
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 634-635
Sharma, Amol MD, FACG
doi : 10.14309/ajg.0000000000001233
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 636
Kumar, Anand Raman MD, MPH
doi : 10.14309/ajg.0000000000001234
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 637
Attard, Thomas M. MD1,2; Burke, Carol A. MD3; Hyer, Warren MD4; Durno, Carol MD; Hurley, Karen E. PhD6; Lawson, Caitlin E. MS, CGC1; Church, James MD7; Cohen, Shlomi MD8; Maddux, Michele H. PhD1,2; on behalf of the Pediatric Committee of the American College of Gastroenterology
doi : 10.14309/ajg.0000000000001140
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 638-646
Transition of care (TOC) in adolescents and young adults (AYAs) with chronic gastrointestinal disorders has received increased attention, especially in those with inflammatory bowel disease. AYAs with hereditary polyposis syndromes are a heterogeneous group of patients with overlapping and complex medical needs. These patients are particularly vulnerable because of the risk of loss of continuity of care and subsequent poor disease outcomes. The Pediatric Committee of the American College of Gastroenterology commissioned a report with recommendations on TOC in AYAs with hereditary polyposis syndromes. This report aims at achieving best practice by both pediatric and adult gastroenterologists despite the paucity of published evidence in this population reflected in the included PRISMA report. Therefore, the group extrapolated findings from the literature related to other chronic gastrointestinal disorders, and a high degree of expert consensus was scored for all recommendations. The report addresses TOC through identifying shared domains followed by specific recommendations in disease management, including models of care, providers and patient and socioeconomic factors relevant to TOC. Areas of strong emphasis include the need for early planning, flexibility in the transition process to maintain continuity during major surgical procedures, patient and family psychological readiness, liaison among team members addressing transition, and changing insurance coverage in this population.
Gupta, Sanchit MD, MS1,2; Mullish, Benjamin H. MB BChir, PhD3; Allegretti, Jessica R. MD, MPH1,2
doi : 10.14309/ajg.0000000000001075
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 647-656
Fecal microbiota transplantation (FMT) has been recommended in clinical guidelines for the treatment of recurrent Clostridioides difficile infection (CDI). However, it is considered investigational by most regulatory agencies. As the adoption of FMT has increased from a small group of CDI experts alone to more widespread use, there has been a corresponding increase in concern regarding potential risk. FMT is largely considered a safe procedure although risks described range from mild gastrointestinal symptoms to serious infection. Currently, there is variability in how “FMT” is characterized specifically regarding testing approach, which, in turn, impacts the risk profile. This has been highlighted by the rare cases of multidrug-resistant organisms, Shiga toxin–producing Escherichia and enteropathogenic E. coli, recently reported, where these organisms were not screened. These cases have prompted additional screening mandates from the US Food and Drug Administration (FDA), which has maintained its policy of enforcement discretion for the use of FMT for CDI not responding to standard therapy. Here, we examine the evolving risk landscape of FMT.
Barakat, Monique T. MD, PhD1; Adler, Douglas G. MD, FACG, AGAF, FASGE2
doi : 10.14309/ajg.0000000000001102
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 657-665
A comprehensive understanding of gastrointestinal anatomy is essential for performance of any endoscopic procedure. Surgical approaches to therapy have become increasingly common in the past decade, which has resulted in a substantial proportion of patients with surgically altered anatomy who require endoscopy. In parallel with the obesity epidemic, bariatric surgery for obesity management has been widely adopted. In response to these trends, gastroenterologists must become familiar with patient anatomy after these surgical interventions and understand the implications of this altered anatomy on the current array of available endoscopic modalities for diagnosis and therapy. This review describes the range of surgically altered anatomy commonly encountered in the upper gastrointestinal tract. For each foregut location—esophagus, stomach, and small bowel—we describe indications for and specific details of the range of common surgical approaches affecting this regional anatomy. We then provide an endoscopic roadmap through the altered anatomy resulting from these surgical interventions. Finally, we address the impact of postsurgical anatomy on performance of endoscopic ultrasound and endoscopic retrograde cholangiopancreatography, with guidance surrounding how to successfully execute these procedures. Evolution of endoscopic approaches over time might be expected to enhance the safety and efficacy of these interventions in patients with surgically altered anatomy.
Baron, Todd H. MD, MASGE
doi : 10.14309/ajg.0000000000001090
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 666-668
Nearly 25 years after its initial description, endoscopic therapy of walled-off pancreatic necrosis has become widely accepted. Endoscopic therapy is composed of transmural placement of stents, now most commonly lumen-apposing metal stents and removal of solid debris, if needed. Removal of solid debris can be achieved with irrigation provided by percutaneously or endoscopically placed (nasocystic) tubes or by mechanically through direct necrosectomy. This editorial provides commentary on the use of hydrogen peroxide instilled at the time of direct necrosectomy for treatment of walled-off pancreatic necrosis.
Toledo, Frederico G.S. MD1; Chari, Suresh MD2; Yadav, Dhiraj MD, MPH3
doi : 10.14309/ajg.0000000000001104
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 669-670
Type 2 diabetes is a known risk factor for the development of pancreatic adenocarcinoma. However, the mechanisms behind this epidemiological association remain unclear. Whether it is hyperglycemia or insulin resistance that increases the risk of pancreatic adenocarcinoma is a question that has yet to be settled. A new study by Kim et al published in The American Journal of Gastroenterology shows that the presence of insulin resistance independently increases pancreatic cancer mortality even in individuals without diabetes and hyperglycemia. The study's findings and implications to our understanding of pancreatic cancer risk are discussed.
Ha, Christina MD1
doi : 10.14309/ajg.0000000000001199
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 671-672
This editorial comments on the study by Khan et al. that describes potential risk of acute myeloid leukemia or myeloproliferative disorder among thiopurine therapy.
Kok, Beverley MBBS1; McNeely, Margaret PhD2; Watt, Makayla BSc1; Tandon, Puneeta MD1
doi : 10.14309/ajg.0000000000001198
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 673-674
Exercise interventions in patients with cirrhosis have been shown to improve muscle mass and strength, aerobic capacity, fatigue, and quality of life. There are gaps, however, including limited data on patients with decompensated cirrhosis and home-based routines. This editorial comments on the randomized controlled trial by Lai et al. investigating a home-based exercise intervention in patients with cirrhosis and its impact on physical frailty. Although the trial yielded negative results, the lessons learned should help refine and propel future work.
Frei, Nicola F. MD1; Khoshiwal, Amir M. MD1; Konte, Kadere MD1; Bossart, Emily A. PhD2; Stebbins, Katelyn2; Zhang, Yi PhD2; Pouw, Roos E. MD, PhD3; ten Kate, Fiebo J.W. MD, PhD4; Seldenrijk, Kees A. MD, PhD5; Meijer, Sybren L. MD, PhD6; Critchley-Thorne, Rebecca J. PhD2; Bergman, Jacques J.G.H.M. MD, PhD1
doi : 10.14309/ajg.0000000000001037
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 675-682
Low-grade dysplasia (LGD) is the best predictor of neoplastic progression in Barrett's esophagus (BE). Most LGD cases are downstaged to nondysplastic (ND) BE on expert pathologist review, which is prone to interobserver variation and not widely available. Recent studies indicate that a risk prediction assay (TissueCypher) risk stratifies patients with NDBE for neoplastic progression. We aimed to investigate whether this risk prediction assay predicts neoplastic progression in BE patients with LGD.
Wang, Qiao-Li MD, PhD1; Ness-Jensen, Eivind MD, PhD1,2,3; Santoni, Giola PhD1; Xie, Shao-Hua MD, PhD1; Lagergren, Jesper MD, PhD1,4
doi : 10.14309/ajg.0000000000001094
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 683-691
Esophageal squamous cell carcinoma (ESCC) carries a poor prognosis, but earlier tumor detection would improve survival. We aimed to develop and externally validate a risk prediction model based on exposure to readily available risk factors to identify high-risk individuals of ESCC.
Shoaibi, Azza PhD1; Fortin, Stephen Patrick PharmD, MS1; Weinstein, Rachel PhD1; Berlin, Jesse A. ScD2; Ryan, Patrick PhD1
doi : 10.14309/ajg.0000000000001153
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 692-699
Famotidine has been posited as a potential treatment for coronavirus disease 2019 (COVID-19). We compared the incidence of COVID-19 outcomes (i.e., death and death or intensive services use) among hospitalized famotidine users vs proton pump inhibitors (PPIs) users, hydroxychloroquine users, or famotidine nonusers separately.
Messallam, Ahmed A. MD1; Adler, Douglas G. MD2; Shah, Raj J. MD3; Nieto, Jose M. DO4; Moran, Robert MD5; Elmunzer, B. Joseph MD5; Cosgrove, Natalie MD6; Mullady, Dan MD6; Singh, Harkirat MD7; Cote, Gregory MD5; Papachristou, Georgios I. MD, PhD8; Othman, Mohamed O. MD9; Zhang, Chao PhD10; Javaid, Huma MS9; Mercado, Michael BS9; Tsistrakis, Steven MD11; Kumta, Nikhil A. MD, MS11; Nagula, Satish MD11; Dimaio, Christopher J. MD11; Birch, Madeleine S. BS2; Taylor, Linda Jo RN2; Labarre, Nicolas MD5; Han, Samuel MD3; Hollander, Thomas RN6; Keilin, Steven A. MD1; Cai, Qiang MD, PhD1; Willingham, Field F. MD, MPH1
doi : 10.14309/ajg.0000000000000987
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 700-709
Endoscopic necrosectomy has emerged as the preferred treatment modality for walled-off pancreatic necrosis. This study was designed to evaluate the safety and efficacy of direct endoscopic necrosectomy with and without hydrogen peroxide (H2O2) lavage.
Lin, Otto S. MD, MSc1; La Selva, Danielle BA1; Kozarek, Richard A. MD1; Weigel, Wade MD2; Beecher, Ryan CRNA, MSN2; Gluck, Michael MD1; Chiorean, Michael MD1; Boden, Elisa MD1; Venu, Nanda MD1; Krishnamoorthi, Rajesh MD1; Larsen, Michael MD1; Ross, Andrew MD1
doi : 10.14309/ajg.0000000000000969
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 710-716
Nurse-Administered Propofol Continuous Infusion Sedation (NAPCIS) is a new nonanesthesia propofol delivery method for gastrointestinal endoscopy. NAPCIS is adopted from the computer-assisted propofol sedation (CAPS) protocol. We evaluated the effectiveness, efficiency, and safety of NAPCIS in low-risk subjects.
Lai, Jennifer C. MD, MBA1; Dodge, Jennifer L. MPH1; Kappus, Matthew R. MD2; Wong, Randi BS1; Mohamad, Yara MBBS1; Segev, Dorry L. MD, PhD3; McAdams-DeMarco, Mara PhD3,4
doi : 10.14309/ajg.0000000000001113
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 717-722
We developed the strength training intervention (STRIVE), a home-based exercise program targeting physical function in patients with cirrhosis. In this pilot study, we aimed to evaluate the safety and efficacy of STRIVE.
Pons, Monica MD1; Augustin, Salvador MD1,2; Scheiner, Bernhard MD3,4; Guillaume, Maeva MD5; Rosselli, Matteo MD6; Rodrigues, Susana G. MD7; Stefanescu, Horia MD8; Ma, Mang M. MD9; Mandorfer, Mattias MD3,4; Mergeay-Fabre, Mayka MD5; Procopet, Bogdan MD8; Schwabl, Philipp MD3,4; Ferlitsch, Arnulf MD3,4,10; Semmler, Georg MD3,4; Berzigotti, Annalisa MD7,11; Tsochatzis, Emmanuel MD6; Bureau, Christophe MD5; Reiberger, Thomas MD3,4; Bosch, Jaime MD2,7,11; Abraldes, Juan G. MD9; Genescà, Joan MD1,2
doi : 10.14309/ajg.0000000000000994
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 723-732
We aimed to explore the prevalence of portal hypertension in the most common etiologies of patients with compensated advanced chronic liver disease (cACLD) and develop classification rules, based on liver stiffness measurement (LSM), that could be readily used to diagnose or exclude clinically significant portal hypertension (CSPH) in clinical practice.
Yamada, Gen MD, MPH1; Hagiwara, Yasuhiro PhD, MPH1; Kimura, Takeshi MD, PhD, MPH2; Takeuchi, Yoshinori DVM, PhD, MPH1; Oba, Koji PhD1; Masuda, Katsunori MD, PhD2; Matsuyama, Yutaka PhD1
doi : 10.14309/ajg.0000000000001030
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 733-740
We aimed to investigate the effect of recent short-term weight gain on the incidence of nonalcoholic fatty liver disease (NAFLD) in nonobese (body mass index < 25 kg/m2) participants.
Khan, Nabeel MD1,2; Patel, Dhruvan MD2; Trivedi, Chinmay MBBS1; Kavani, Himanshu MBBS3; Pernes, Tyler BA1; Medvedeva, Elina MS1; Lewis, James MD2,4; Xie, Dawei PhD4,5; Yang, Yu-Xiao MD1,2,4,5
doi : 10.14309/ajg.0000000000001058
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 741-747
Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are rare myeloid clonal disorders that commonly affect the elderly population and have poor prognosis. There are limited data on the risk of AML/MDS among patients with inflammatory bowel disease (IBD), especially on the impact of thiopurines (TPs).
Shah, Eric D. MD, MBA1; Chang, Lin MD2; Salwen-Deremer, Jessica K. PhD1,3; Gibson, Peter R. MD4; Keefer, Laurie PhD5; Muir, Jane G. PhD4; Eswaran, Shanti MD6; Chey, William D. MD6
doi : 10.14309/ajg.0000000000000989
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 748-757
Insurance coverage is an important determinant of treatment choice in irritable bowel syndrome (IBS), often taking precedence over desired mechanisms of action or patient goals/values. We aimed to determine whether routine and algorithmic coverage restrictions are cost-effective from a commercial insurer perspective.
Vollebregt, Paul F. MD1; Burgell, Rebecca E. MD, PhD1,2; Hooper, Richard L. PhD3; Knowles, Charles H. BChir, PhD, FRCS1; Scott, S. Mark PhD1
doi : 10.14309/ajg.0000000000001039
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 758-768
Normal bowel function requires intact sensory pathways. Diminished rectal sensation (rectal hyposensitivity [RH]) is associated with constipation, although its clinical importance remains unclear.
Midenfjord, Irina MSc1; Borg, Adam MS1; T?rnblom, Hans MD, PhD1; Simrén, Magnus MD, PhD1,2
doi : 10.14309/ajg.0000000000001038
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 769-779
Psychological alterations are common and considered important for symptom generation in irritable bowel syndrome (IBS). However, the possible cumulative effect of having multiple psychological alterations on gastrointestinal (GI) symptom severity in IBS is largely unknown.
Baker, Jason R. PhD1; Chey, William D. MD1; Watts, Lydia BS1; Armstrong, Moira BS1; Collins, Kristen BS1; Lee, Allen A. MD1; Dupati, Ajith BS1; Menees, Stacy MD1; Saad, Richard J. MD1; Harer, Kimberly MD1; Hasler, William L. MD1
doi : 10.14309/ajg.0000000000001110
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 780-787
The North American Consensus guidelines for glucose breath testing (GBT) for small intestinal bacterial overgrowth (SIBO) incorporated changes in glucose dosing and diagnostic cutoffs. We compared GBT positivity based on hydrogen and methane excretion and quantified symptoms during performance of the North American vs older modified Rome Consensus protocols.
Tapia, German PhD1; Chud?, Kate?ina MSc2; Kahrs, Christian R. MD, PhD3; Stene, Lars C. PhD1; Kramna, Lenka PhD2; M?rild, Karl MD, PhD4; Rasmussen, Trond MSc5; R?nningen, Kjersti S. MD, PhD6; Cinek, Ond?ej MD, PhD2; St?rdal, Ketil MD, PhD1,3
doi : 10.14309/ajg.0000000000001003
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 788-795
To test whether parechovirus and anellovirus, frequent enteric viruses, were associated with subsequent celiac disease (CD). We hypothesized that children who later developed CD would have increased frequency of parechovirus infections before transglutaminase 2 (TG2) antibody development. Anellovirus testing was exploratory, as a potential marker of immune status.
LeBrett, Wendi G. MD1; Chen, Frank W. MD1; Yang, Liu MD, MPH1; Chang, Lin MD1
doi : 10.14309/ajg.0000000000001052
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 796-807
Pain control is an important management approach for many gastrointestinal conditions. Because of the ongoing opioid crisis, public health efforts have focused on limiting opioid prescriptions. This study examines national opioid prescribing patterns and factors associated with opioid prescriptions for gastrointestinal conditions.
Khan, Nabeel MD1,2; Patel, Dhruvan MD2; Xie, Dawei Ph D3,4; Pernes, Tyler BA1; Lewis, James MD2,3; Yang, Yu-Xiao MD1,2,3,4
doi : 10.14309/ajg.0000000000001012
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 808-810
The clinic course of SARS-CoV-2 among patients with inflammatory bowel disease (IBD) has been extensively studied. However, there is a paucity of data on whether patients with IBD have an increased risk of developing SARS-CoV-2 with compared with patients without IBD.
Han, Samuel MD1; Kolb, Jennifer M. MD1; Hosokawa, Patrick PhD2; Friedman, Chloe MPH3; Fox, Charlie MD1; Scott, Frank I. MD1; Lieu, Christopher H. MD4; Vajravelu, Ravy K. MD5; McCarter, Martin MD3; Murphy, Caitlin C. PhD6; Cook, Michael B. PhD7; Gleisner, Ana MD3; Falk, Gary W. MD5; Katzka, David A. MD8; Wani, Sachin MD1
doi : 10.14309/ajg.0000000000001046
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 811-815
Using the National Cancer Database, we assessed the relationship between facility overall esophageal adenocarcinoma (EAC) case volume and survival.
Oude Nijhuis, Renske A.B. MD1; Curvers, Wouter L. MD, PhD2; van der Ende, Mirjam MSc2; Herregods, Thomas V.K. MD, PhD1; Schuitenmaker, Jeroen M. MD1; Smout, Andreas J.P.M. MD, PhD1; Bredenoord, Albert J. MD, PhD1
doi : 10.14309/ajg.0000000000001064
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 816-820
This study aimed to assess the diagnostic yield of routine esophageal biopsies in patients with refractory reflux symptoms.
Kurlander, Jacob E. MD, MS1,2,3; Barnes, Geoffrey D. MD, MSc1,3,4; Sukul, Devraj MD, MS1,3,4; Helminski, Danielle MPH1; Kokaly, Alex N. MD, MHSA5; Platt, Kevin MD1; Gurm, Hitinder MD, MBBS1,3,4; Saini, Sameer D. MD, MS1,2,3
doi : 10.14309/ajg.0000000000001134
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 821-824
Gastrointestinal bleeding is a morbid complication of dual antiplatelet therapy (DAPT). We evaluated the extent to which contemporary trials of DAPT included steps to ensure appropriate use of proton pump inhibitor (PPI) gastroprotection and reported rates of PPI use.
Houwen, Britt B. S. L. MD1; Mostafavi, Nahid PhD2; Vleugels, Jasper L. A. MD, PhD1; Hüneburg, Robert MD, PhD3,4; Lamberti, Christof MD, PhD5; Rivero-S?nchez, Liseth MD, PhD6; Pellisé, Mar?a MD, PhD6; Stoffel, Elena M. MD, PhD7; Syngal, Sapna MD, PhD8-10; Haanstra, Jasmijn F. MD11; Koornstra, Jan. J. MD, PhD11; Dekker, Evelien MD, PhD1; Hazewinkel, Yark MD, PhD1,12
doi : 10.14309/ajg.0000000000001138
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 825-828
The additional diagnostic value of dye-based chromoendosocpy (CE) for surveillance of patients with Lynch syndrome is subject of debate.
Agarwal, Amol MD1,2; Zhang, Talan MS1; Ravindran, Nishal MD1; Thuluvath, Paul J. MD1,2; Maheshwari, Anurag MD1,2
doi : 10.14309/ajg.0000000000001143
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 829-832
We evaluated the off-label use of multitarget stool DNA (mt-sDNA) testing in the primary care setting.
Black, Christopher J. MBBS(Hons)1,2; Ford, Alexander C. MD1,2
doi : 10.14309/ajg.0000000000000976
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 833-834
Borup, Christian MD1,2; Munck, Lars K. MD, DMSci1,2
doi : 10.14309/ajg.0000000000001023
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 834
Morton, Adam FRACP1
doi : 10.14309/ajg.0000000000001011
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 835
Alukal, Joseph J. MD1; Thuluvath, Paul J. MD, FRCP1
doi : 10.14309/ajg.0000000000001047
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 835-836
Soni, Dipesh MBBS1; Roy, Akash MD2; De, Arka MD, DM2; Verma, Nipun MD, DM2; Singh, Virendra MD, DM, FASGE2
doi : 10.14309/ajg.0000000000001010
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 836-837
Tapper, Elliot B. MD1,2
doi : 10.14309/ajg.0000000000001048
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 837
Gupta, Vishal MS, MCh, FACS1; Jain, Gaurav MD2
doi : 10.14309/ajg.0000000000000973
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 838
Ierardi, Anna Maria MD1; Del Giudice, Costantino MD2; Coppola, Andrea MD3; Carnevale, Aldo MD4; Giganti, Melchiore MD4; Renzulli, Matteo MD5; Tacher, Vania MD6; Urbano, Jose MD7; Kobeiter, Hicham MD6; Loffroy, Romaric MD8; Sapoval, Marc MD2; Carrafiello, Gianpaolo MD1,9
doi : 10.14309/ajg.0000000000000978
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 838-840
Rolny, Peter MD, PhD1; Papachrysos, Nikolaos MD, PhD1
doi : 10.14309/ajg.0000000000000984
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 840-841
Niedermaier, Tobias MPH, PhD1; Balavarca, Yesilda PhD2,3; Brenner, Hermann MD, MPH, PhD1,2,3
doi : 10.14309/ajg.0000000000001049
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 841
Sonnenberg, Amnon MD, MSc1,2
doi : 10.14309/ajg.0000000000000986
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 841-842
Dong, Elizabeth MD1; Wu, Bechien U. MD, MPH2
doi : 10.14309/ajg.0000000000000977
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 842-843
Sharma, Sanchit MD1; Kumar, Ramesh MD, DM2; Shalimar, MD, DM1
doi : 10.14309/ajg.0000000000000979
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 843-844
Martin, Tracey A. MD1; Wan, David W. MD1
doi : 10.14309/ajg.0000000000001098
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 844
Tang, Xia MS1; Shao, Yue MS2; Yi, Xin PhD3; Newey, Paul J. DPhil4; Li, Dewei MD2; Ding, Keyue PhD1; and Gastrointestinal Cancer Evolution Study Group
doi : 10.14309/ajg.0000000000001004
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 844-847
Eisa, Mohamed MD1; Kennedy, Rachel MD1; Teferra, Rahel MD1; Heckroth, Matthew MD1; Eiswerth, Michael DO1; McClain, Craig MD1
doi : 10.14309/ajg.0000000000001002
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 847-848
Ma, Tianyi MD1; Wu, Meng MD1
doi : 10.14309/ajg.0000000000001008
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 848-849
Mather, Jeffrey BS, MS1
doi : 10.14309/ajg.0000000000001068
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 849-850
Staller, Kyle MD, MPH; Cash, Brooks D. MD
doi : 10.14309/ajg.0000000000001114
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 851
doi : 10.14309/ajg.0000000000001181
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 852
doi : 10.14309/ajg.0000000000001235
The American Journal of Gastroenterology: April 2021 - Volume 116 - Issue 4 - p 853
آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟